Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Alcohol withdrawal syndrome in medical patients

Justine S. Gortney, PharmD, BCPS, Joshua N. Raub, PharmD, BCPS, Pragnesh Patel, MD, Lianne Kokoska, PharmD, Mae Hannawa, PharmD and Amy Argyris, PharmD, BCPS
Cleveland Clinic Journal of Medicine January 2016, 83 (1) 67-79; DOI: https://doi.org/10.3949/ccjm.83a.14061
Justine S. Gortney
Assistant Professor, Director of Assessment, Division of Pharmacy, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Joshua N. Raub
Clinical Pharmacist Specialist in Internal Medicine, Assistant Program Director, Pharmacy Practice, Detroit Receiving Hospital, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragnesh Patel
Assistant Professsor, Wayne State School of Medicine, Division of Geriatrics, University Health Center, Detroit Receiving Hospital, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lianne Kokoska
United Physicians, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mae Hannawa
Clinical Pharmacist, Detroit Receiving Hospital, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Argyris
Clinical Pharmacist Specialist in Internal Medicine, Harper University Hospital, Detroit, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Symptoms of alcohol withdrawal syndrome

    Time of appearance after cessationSymptoms
    6–12 hoursMinor withdrawal symptoms: insomnia, tremulousness, mild anxiety, gastrointestinal upset, headache, diaphoresis, palpitations, anorexia
    12–24 hoursaAlcoholic hallucinosis: visual, auditory, or tactile hallucinations
    24–48 hoursbWithdrawal seizures: generalized tonic-clonic seizures
    48–72 hourscAlcohol withdrawal delirium (delirium tremens): hallucinations (mainly visual), disorientation, tachycardia, hypertension, low-grade fever, agitation, diaphoresis
    • ↵a Symptoms generally resolve within 48 hours.

    • ↵b Symptoms reported as early as 2 hours after cessation.

    • ↵c Symptoms as late as 5 days.

    • From Bayard M, McIntyre J, Hill KR, Woodside J, Jr. Alcohol withdrawal syndrome. Am Fam Physician 2004; 69:1443–1450. Reproduced with permission from the American Academy of Family Physicians.

    • View popup
    TABLE 2

    The CIWA-Ar scale for assessing alcohol withdrawal syndrome

    SymptomObservationPoints
    Nausea and vomitinga
    (Ask “Do you feel sick to your stomach? Have you vomited?”)
    No nausea and vomiting0
    Intermittent nausea with dry heaves4
    Constant nausea, frequent dry heaves, vomiting7
    Tremora
    (Observe with arms extended and apart.)
    No tremor0
    No tremor visible, but can be felt, fingertip to fingertip1
    Moderate tremor with arms extended4
    Severe tremor, even with arms not extended7
    Paroxysmal sweatsaNo sweat visible0
    Beads of sweat obvious on forehead4
    Drenching sweats7
    Anxietya
    (“Do you feel nervous?”)
    No anxiety (at ease)0
    Mildly anxious1
    Moderately anxious or guarded, so anxiety is inferred4
    Equivalent to acute panic states that occur in severe delirium or acute schizophrenic reactions7
    AgitationaNormal activity0
    Somewhat more than normal activity1
    Moderately fidgety and restless4
    Paces back and forth during most of interview or constantly thrashes about7
    Tactile disturbances
    (“Do you have any itching, pins-and-needles sensations, burning, or numbness, or do you feel like bugs are crawling on or under your skin?”)
    None0
    Very mild itching, pins-and-needles sensation, burning, or numbness1
    Mild itching, pins-and-needles sensation, burning, or numbness2
    Moderate itching, pins-and-needles sensation, burning, or numbness3
    Moderately severe hallucinations4
    Severe hallucinations5
    Extremely severe hallucinations6
    Continuous hallucinations7
    Auditory disturbances
    (“Are you more aware of sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things you know are not there?”)
    Not present0
    Very mild harshness or ability to frighten1
    Mild harshness or ability to frighten2
    Moderate harshness or ability to frighten3
    Moderately severe hallucinations4
    Severe hallucinations5
    Extremely severe hallucinations6
    Continuous hallucinations7
    Visual disturbances
    (“Does the light appear to be too bright? Is its color different? Does it hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things you know are not there?”)
    Not present0
    Very mild sensitivity1
    Mild sensitivity2
    Moderate sensitivity3
    Moderately severe hallucinations4
    Severe hallucinations5
    Extremely severe hallucinations6
    Continuous hallucinations7
    Headache, fullness in head
    (“Does your head feel different? Do you feel like there is a band around your head?”)
    Do not rate for dizziness or lightheaded-ness. Otherwise, rate severity.
    Not present0
    Very mild1
    Mild2
    Moderate3
    Moderately severe4
    Severe5
    Very severe6
    Extremely severe7
    Orientation and clouding of sensorium
    (“What day is this? Where are you? Who am I?”)
    Oriented and can do serial additions0
    Cannot do serial additions or is uncertain about date1
    Date disorientation by no more than 2 calendar days2
    Date disorientation by more than 2 calendar days3
    Disoriented to place or person, or both4
    Total CIWA-Ar scoreMaximum possible: 67
    • ↵a If symptoms lie between the point categories listed, it is acceptable to rate as a whole number in between. CIWA-Ar = revised Clinical Institute Withdrawal Assessment for Alcohol15

    • Based on Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84:1353–1357.

    • View popup
    TABLE 3

    Pharmacokinetic characteristics of benzodiazepines

    ChlordiazepoxideDiazepamLorazepamOxazepam
    Dosage formsOralOral, gel, intramuscular, intravenousOral, intramuscular, intravenousOral
    Equivalent dosages25 mg5 mg1 mg15 mg
    Half-life5–15 hours with active metabolites > 100 hours30–60 hours with active metabolites >100 hours10–20 hours5–20 hours
    Active metabolitesDesmethylchlordiazepoxide, desmoxepam, desmethyldiazepamDesmethyldiazepamNone None
    Lipid solubilityLess lipophilic than diazepam; slower onset of actionHighly lipophilic; quick onset of actionLess lipophilic than diazepam; slower onset of actionLess lipophilic than diazepam; slower onset of action
    Effect of hepatic diseaseHalf-life increases in patients with cirrhosisHalf-life increases in patients with cirrhosis, acute viral hepatitis, chronic active hepatitisHalf-life increases in patients with cirrhosisHalf-life increases in patients with cirrhosis
    Effect of renal diseaseNo effectDecreases protein bindingHalf-life increases; impaired eliminationNo effect
    Effect of older ageSlower absorption; half-life increasesHalf-life increases; decreased protein bindingNo effect on half-life; decreased protein bindingNo effect on half-life; decreased protein binding
    • Bird RD, Makela EH. Alcohol withdrawal: what is the benzodiazepine of choice? Ann Pharmacother 1994; 28:67–71. Copyright 1994, Annals of Pharmacotherapy; Reproduced and adapted with permission from SAGE Publications, Inc.

    • View popup
    TABLE 4

    Trials comparing inpatient symptom-triggered vs fixed-dosing benzodiazepine therapy in alcohol withdrawal syndrome

    Saitz et al16Jaeger et al17Daeppen et al18Weaver et al19Reoux and Miller20
    No. of patients10121611718340
    Type of programAlcohol withdrawal inpatient treatment programRetrospective, adult medicine patientsAlcohol withdrawal inpatient treatment programProspective, adult medicine patientsAddiction unit vs medical and psychiatric services
    Duration and monitoring4 days; CIWA-Ar scores every 8 hours and 1 hour after medication doseUp to 7 days; CIWA-Ar scores every 1–2 hours3 days; CIWA-Ar scores every 30 minutesCIWA-Ar every 4 hours2 to 8 days; CIWA-Ar scores every 8 hours
    Symptom-triggered protocolIf CIWA-Ar ≥ 8, chlordiazepoxide 20–100 mg every hourIf CIWA-Ar > 10, chlordiazepoxide 50–100 mg with repeated dosesPlacebo every 6 hours
    If CIWA-Ar 8–15, oxazepam 15 mg
    If CIWA-Ar > 15, oxazepam 30 mg
    If CIWA-Ar 6–9, lorazepam 0.5 mg intravenously or orally;
    If 10–19, 2 mg
    If 20–29, 3 mg
    if 30–39, 4 mg
    If CIWA-Ar ≥ 10, oxazepam 30 mg or chlordiaz-epoxide 50 mg every hour until < 10
    Fixed scheduleChlordiazepoxide 50 mg every 6 hours for 4 doses, then 25 mg every 6 hours for 8 dosesUsual care: tapering, fixed-dose regimen, or sporadic dosing by medical staffOxazepam 30 mg every 6 hoursLorazepam 2 mg every 4 hours for 48 hours, then 1 mg every 4 hours for 24 hours, then 0.5 mg every 4 hours for 24 hoursAs ordered by attending physician
    Total dosea100 vs 425 mg
    (P < .001)
    Benzodiazepine equivalents
    20.1 vs 20.1 mg
    37.5 vs 231.4 mg
    (P < .001)
    Lower with symptom-triggered protocolBenzodiazepine equivalents 82.7 vs 367.5 mg
    (P < .01)
    Duration of therapy (hours)a9 vs 68
    (P < .001)
    44.9 vs 55.520 vs 62.7
    (P < .001)
    —10.7 vs 20.7
    (P < .01)
    CIWA-Ar score differencesaNot significantNot reportedP < .01P < .01Not reported
    OutcomesaDelirium tremens (DTs) 2% vs 6%
    Readmission in 30 days 6% vs 8%
    DTs
    6.9% vs 20.5%
    (P < .04)
    No DTs
    One seizure in symptom-triggered group
    No DTs or seizures in either group
    Median length of stay 3 days in both groups
    No DTs, seizures, or adverse drug events in either group
    Oversedation and hypotension in one patient in usual-care group
    • ↵a Symptom-triggered group vs fixed-schedule group.

    • CIWA-Ar = revised Clinical Institute Withdrawal Assessment for Alcohol scale (Table 1)

    • View popup
    TABLE 5

    Examples of symptom-triggered dosing and CIWA-Ar scores

    CIWA-Ar scoreChlordiazepoxide dose (oral)aLorazepam dose (oral or intravenous)aReassess CIWA-Ar and vital signs, and redose
    0–7No medication necessaryNo medication necessaryEvery 2 hours
    8–1025–50 mg1–2 mgEvery 2 hours
    11–1550–75 mg2–3 mgEvery 1–2 hours
    16–1975–100 mg3–4 mgEvery 1–2 hours
    20 or greaterEvaluation for patient transfer to intensive care unit
    CIWA-Ar < 8 for three consecutive checksReassess or redose to every 4 hours. If score remains < 8 every 4 hours on three checks, reassess or redose every 8 hours. If CIWA-Ar score is < 8 for 48 hours, discontinue monitoring.
    • ↵a Patients with liver failure and elderly patients should be started on lower doses. CIWA-Ar = revised Clinical Institute Withdrawal Assessment for Alcohol scale (Table 1)

    • Based on references 15, 16, and 19.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 83 (1)
Cleveland Clinic Journal of Medicine
Vol. 83, Issue 1
1 Jan 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Alcohol withdrawal syndrome in medical patients
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Alcohol withdrawal syndrome in medical patients
Justine S. Gortney, Joshua N. Raub, Pragnesh Patel, Lianne Kokoska, Mae Hannawa, Amy Argyris
Cleveland Clinic Journal of Medicine Jan 2016, 83 (1) 67-79; DOI: 10.3949/ccjm.83a.14061

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Alcohol withdrawal syndrome in medical patients
Justine S. Gortney, Joshua N. Raub, Pragnesh Patel, Lianne Kokoska, Mae Hannawa, Amy Argyris
Cleveland Clinic Journal of Medicine Jan 2016, 83 (1) 67-79; DOI: 10.3949/ccjm.83a.14061
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • CAN LEAD TO DELIRIUM TREMENS
    • ASSESSMENT SCALES FOR ALCOHOL WITHDRAWAL SYNDROME
    • BASELINE ASSESSMENT AND EARLY SUPPORTIVE CARE
    • PRIMARY DRUG THERAPIES FOR MEDICAL INPATIENTS
    • ADJUNCTIVE THERAPIES
    • RECOMMENDATIONS FOR DRUG THERAPY AND SUPPORTIVE CARE
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Prevention of alcohol withdrawal syndrome in the surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Critical Care
  • Drug Therapy
  • Emergency Medicine
  • Hepatology
  • Hospital Medicine
  • Mental Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire